Lev Pharmaceuticals’ Hereditary Angioedema Therapy Cinryze Could Reach Market In Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Second-generation C1 inhibitor has “tremendous body of safety and efficacy data” behind it from decades of use in Europe, CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Lev’s Cinryze Wins Unanimous Advisory Committee Support
Postmarketing studies likely will be required for what could be the first U.S. treatment for hereditary angioedema.
Lev’s Cinryze Wins Unanimous Advisory Committee Support
Postmarketing studies likely will be required for what could be the first U.S. treatment for hereditary angioedema.
With Few Questions From FDA, Cinryze Seems Set For Smooth Committee Review
FDA will review Cinryze only for prophylaxis of hereditary angioedema at Blood Products advisory panel meeting May 2, leaving open the possibility of a split indication.